Unlabelled: We assessed the potential clinical utility of levels of p53-specific antibodies as a novel serum biomarker of prostate cancer that could be used in conjunction with level of PSA.
Material And Methods: Serum levels of p53-specific antibodies in patients with relapsed, newly diagnosed prostate cancer and in patients with benign prostate hyperplasia were quantified by an enzyme-linked immunoabsorbent assay.
Result: There was no significant difference (P=0.
A 67-year-old Japanese woman first visited to the hospital in regard to episodes of a 6 months history of difficulty on urination. Her perineum was mild whitish, and labia majorae were all adhered with only a pinhole-sized opening. A labial incision was performed under a spinal anesthesia.
View Article and Find Full Text PDF